Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of VEGF Trap (Ziv-Aflibercept) in Recurrent/Metastatic Thyroid Cancer
NCT00729157Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2008
- Primary completion
- Oct 2012
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in differentiated thyroid carcinoma (DTC), sponsored by National Cancer Institute. Started Aug 2008; status: completed.
02
Drugs
aflibercept
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT00729157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00729157.